Search hospitals > Quebec > MONTREAL
CHUM-Centre Hospitalier de l'Universite de Montreal
Claim this profileMONTREAL, Quebec H2X 3E4
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Prostate Cancer
Conducts research for Cancer
Conducts research for Pancreatic Cancer
466 reported clinical trials
99 medical researchers
Summary
CHUM-Centre Hospitalier de l'Universite de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Cancer, Pancreatic Cancer and other specialties. CHUM-Centre Hospitalier de l'Universite de Montreal is involved with conducting 466 clinical trials across 623 conditions. There are 99 research doctors associated with this hospital, such as Daniel Von Renteln, MD, Diane Provencher, MD, FRCSC, Jean Raymond, MD, and Moishe Liberman, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Daniel Von Renteln, MDCentre Hospitalier de l'Université de Montréal (CHUM)2 years of reported clinical research
Studies Colorectal Cancer
Studies Colonic Polyps
14 reported clinical trials
19 drugs studied
Diane Provencher, MD, FRCSCCentre Hospitalier de l'Université de Montréal5 years of reported clinical research
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
13 reported clinical trials
21 drugs studied
Jean Raymond, MDCentre Hospitalier de l'Université de Montréal15 years of reported clinical research
Studies Intracranial Aneurysm
Studies Brain Aneurysm
9 reported clinical trials
14 drugs studied
Moishe Liberman, MDCHUM3 years of reported clinical research
Studies Lung Cancer
Studies Pneumothorax
9 reported clinical trials
13 drugs studied
Clinical Trials running at CHUM-Centre Hospitalier de l'Universite de Montreal
Breast Cancer
Prostate Cancer
Cancer
Lung Cancer
Squamous Cell Carcinoma
Cardiovascular Disease
Cervical Cancer
Non-Small Cell Lung Cancer
Oropharyngeal Cancer
Brain Tumor
sac-TMT + Pembrolizumab
for Breast Cancer
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Recruiting2 awards Phase 35 criteria
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
Sacituzumab Tirumotecan + Pembrolizumab
for Breast Cancer
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Recruiting2 awards Phase 33 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at CHUM-Centre Hospitalier de l'Universite de Montreal?
CHUM-Centre Hospitalier de l'Universite de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Cancer, Pancreatic Cancer and other specialties. CHUM-Centre Hospitalier de l'Universite de Montreal is involved with conducting 466 clinical trials across 623 conditions. There are 99 research doctors associated with this hospital, such as Daniel Von Renteln, MD, Diane Provencher, MD, FRCSC, Jean Raymond, MD, and Moishe Liberman, MD.
Where is CHUM-Centre Hospitalier de l'Universite de Montreal located?
**Centre Hospitalier de l'Université de Montréal (CHUM)**
- **Location:** 1051 Sanguinet Street, Montreal, Quebec, Canada. Features underground city access to Champ-de-Mars metro station.
- **Type:** Public not-for-profit corporation.
- **Funding:** Supported by Quebec taxpayers via the Ministry of Health and Social Services.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at CHUM-Centre Hospitalier de l'Universite de Montreal:
- **Financial Support - CHUM**: For information about financial support, please consult the CHUM website.
- **Université de Montréal Contact**: Reach out at 514 343-6111 or mail to PO Box 6128, Centre-ville Station, Montréal, Quebec, H3C 3J7 for guidance or direction to the appropriate department.
- **Student Financial Assistance - Québec**: Contact the Student Financial Assistance office at the Ministry of Higher Education in Québec at their client services from Monday to Friday, 8:30 a.m. to 12:00 p.m. and 1:00 p.m. to 4:30 p.m., with extended hours on Wednesdays.
What insurance does CHUM-Centre Hospitalier de l'Universite de Montreal accept?
The Centre hospitalier de l'Université de Montréal (CHUM) is a public not-for-profit hospital funded mainly by Quebec taxpayers. CHUM accepts the Régie de l'assurance maladie du Québec (RAMQ) for Quebec residents, covering hospital care, physician services, and certain diagnostics. For those without RAMQ coverage, including international patients, CHUM provides private healthcare options and participates in international medical programs.
What awards or recognition has CHUM-Centre Hospitalier de l'Universite de Montreal received?
The CHUM Research Centre (CRCHUM) at the Centre Hospitalier de l'Universite de Montreal is renowned for its significant contributions to health research, as evidenced by its annual Research Awards of Excellence. It has also earned an "exceptional" rating in the 2020-2026 strategic plan by the Fonds de recherche du Québec — Santé, highlighting its outstanding performance in research activities.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.